道纳米管:对化学电阻的影响
Sanyukta Padmanabhan1, Karina Deniz1, Akshat Sarkari1
1University of Minnesota Twin Cities, Minneapolis, MN, USA.
Results and problems in cell differentiation
|September 6, 2024
概括
道纳米管 (TNTs) 通过使分子转移成为可能,促进细胞间通信和癌症中耐药性. 向TNT提供了一个有希望的治疗策略,以抑制瘤生长和转移.
科学领域:
- 细胞生物学 细胞生物学
- 癌症研究 癌症研究
背景情况:
- 道纳米管 (TNTs) 是细胞连接,促进分子转移.
- TNTs在细胞间通信,耐药性和病毒传播中发挥作用.
- 它们在癌症进展和转移中的作用是越来越多的研究领域.
研究的目的:
- 研究TNTs在癌症进展和转移中的作用.
- 探索TNT作为癌症治疗的潜在治疗点.
- 了解TNT在癌细胞中的形成和功能机制.
主要方法:
- 对癌症生物学中TNTs现有文献的审查.
- 对TNT介导的细胞间通信和药物耐药性机制的分析.
- 讨论针对TNT的潜在治疗策略.
主要成果:
- 瘤细胞可以通过TNT进行癌细胞的沟通和协调.
- 通过货物交换,TNTs有助于药物耐药性的演变.
- 破坏TNTs可能会抑制瘤生长和转移.
结论:
- 在癌症进展,转移和耐药性方面,TNTs至关重要.
- 向TNTs为癌症治疗提供了一个新的治疗途径.
- 进一步研究TNT的形成和功能对于药物发现至关重要.
更多相关视频
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.6K
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.4K
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
